Clinical Trials Logo

Clinical Trial Summary

Techfields Inc. is developing a new investigational prodrug as a topical spray, indicated for relief of the signs and symptoms of ARDS and pneumonia caused by COVID-19. This is a Phase 2, Multicenter, Randomized, Double-blind (Within Dose), Placebo-controlled, Parallel-group, and Dose-range-finding Study to Evaluate the Efficacy and Safety of Active drug Versus Placebo in Treatments for COVID-19 in Hospitalized Adults, relieving of the signs and symptoms of acute respiratory distress syndrome (ARDS) and pneumonia caused by coronavirus disease 2019 (COVID-19).


Clinical Trial Description

A total of approximately 400 eligible patients will be randomly assigned to receive Active Drug low dose (n=80), placebo low dose (n=80), Active Drug high dose (n=160), or placebo high dose (n=80) according to a 1:1:2:1 ratio. The study will be stopped when the last patient completes the double-blind treatment period (end of treatment [EOT]/early termination visit [ETV] on Day 29 + 3 days) and follow-up period. Screening will start when the patient is hospitalized. Each patient enrolled will receive an investigational product (IP; Active Drug or placebo) in a double-blind manner for 28 days (during the double-blind treatment period), starting immediately after all eligibility criteria (including test results) are confirmed. All patients will receive institutional standard of care (SOC) concurrently with their assigned IP. There will be a follow-up visit on Day 36+3 days. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05212818
Study type Interventional
Source Techfields Inc
Contact
Status Recruiting
Phase Phase 2
Start date April 27, 2022
Completion date June 30, 2023

See also
  Status Clinical Trial Phase
Suspended NCT04901676 - Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia Phase 3
Not yet recruiting NCT04534478 - Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19 Phase 4
Active, not recruiting NCT05002517 - Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab Phase 3
Completed NCT05008393 - Efficacy of PJS-539 for Adult Patients With COVID-19. Phase 2
Recruiting NCT04569877 - GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia Phase 2
Not yet recruiting NCT05035589 - The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
Recruiting NCT05042063 - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Recruiting NCT04615429 - Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19 Phase 2
Completed NCT05047653 - RALE Versus CORADS/CT-Severity Score in COVID-19
Active, not recruiting NCT05047016 - Study to Evaluate the Dynamic Consent Model Based on the Blockchain-based Clinical Trial Platform METORY N/A
Recruiting NCT05033847 - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above Phase 2
Active, not recruiting NCT05035524 - A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19 N/A
Completed NCT05065879 - Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes Phase 4
Withdrawn NCT04390217 - LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia Phase 2
Withdrawn NCT04460105 - Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia Phase 1
Suspended NCT04901689 - Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation Phase 3
Not yet recruiting NCT05094596 - Effect of Montelukast Therapy on Clinical Course, Pulmonary Function, and Mortality in Patients With COVID-19 Phase 4
Not yet recruiting NCT05065892 - Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes Phase 4
Not yet recruiting NCT05080257 - Prognostic Value Of Chest Ultrasound (Lung Ultrasound Score) In COVID-19 Pneumonia Patients
Not yet recruiting NCT05077982 - The Long Term Effects of COVID on Pulmonary Function